ABSTRACT
This morphological and immunohistochemical study demonstrates that tumors currently known as "middle ear adenomas" are truly well-differentiated epithelial neuroendocrine tumors (NETs) composed of cells comparable to normal intestinal L cells, and therefore, these tumors resemble hindgut NETs. These tumors show consistent expression of glucagon, pancreatic polypeptide, PYY, and the transcription factor SATB2, as well as generic neuroendocrine markers and keratins. The same L cell markers are expressed by cells within the normal middle ear epithelium. These markers define a valuable immunohistochemical profile that can be used for differential diagnosis of middle ear neoplasms, particularly in distinguishing epithelial NETs from paragangliomas. The discovery of neuroendocrine cells expressing the same markers in non-neoplastic middle ear mucosa opens new areas of investigation into the physiology of the normal middle ear and the pathophysiology of middle ear disorders.
Subject(s)
Adenoma/diagnosis , Ear Neoplasms/diagnosis , Ear, Middle/pathology , L Cells/physiology , Neuroendocrine Tumors/diagnosis , Adenoma/classification , Adenoma/metabolism , Adenoma/pathology , Adult , Aged , Animals , Cell Differentiation , Diagnosis, Differential , Ear Neoplasms/classification , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Ear, Middle/metabolism , Female , Humans , Immunohistochemistry , L Cells/metabolism , L Cells/pathology , Male , Mice , Middle Aged , Neuroendocrine Tumors/classification , Neuroendocrine Tumors/metabolism , Neuroendocrine Tumors/pathology , Retrospective Studies , Terminology as TopicABSTRACT
Patients with non-supernumerary ring chromosome 7 syndrome have an increased incidence of hemangiomas, café-au-lait spots, and melanocytic nevi. The mechanism for the increased incidence of these benign neoplasms is unknown. We present the case of a 22-year-old man with ring chromosome 7 and multiple melanocytic nevi. Two nevi, one on the right ear and the other on the right knee, were biopsied and diagnosed as desmoplastic Spitz nevi. Upon targeted next-generation DNA sequencing, both harbored BRAF fusions. Copy number alterations and fluorescence in situ hybridization (FISH) for BRAF suggested that the fusions arose on the ring chromosome 7. Hence, one reason for increased numbers of nevi in patients with non-supernumerary ring chromosome 7 syndrome may be increased likelihood of BRAF fusions, due to the instability of the ring chromosome.
Subject(s)
Chromosome Disorders , Ear Neoplasms , Nevus, Epithelioid and Spindle Cell , Oncogene Proteins, Fusion , Proto-Oncogene Proteins B-raf , Ring Chromosomes , Skin Neoplasms , Adult , Chromosome Disorders/genetics , Chromosome Disorders/metabolism , Chromosomes, Human, Pair 7/genetics , Chromosomes, Human, Pair 7/metabolism , Chromosomes, Human, Pair 7/physiology , Ear Neoplasms/genetics , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Humans , Male , Nevus, Epithelioid and Spindle Cell/genetics , Nevus, Epithelioid and Spindle Cell/metabolism , Nevus, Epithelioid and Spindle Cell/pathology , Oncogene Proteins, Fusion/genetics , Oncogene Proteins, Fusion/metabolism , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/metabolism , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , Skin Neoplasms/pathologySubject(s)
Ear Neoplasms/diagnosis , Endothelial Cells/pathology , Glomus Jugulare Tumor/diagnosis , Glomus Tympanicum Tumor/diagnosis , Paraganglioma/diagnosis , Adult , Cell Count , Cell Death , Disease Progression , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Endothelial Cells/metabolism , Endothelial Cells/physiology , Glomus Jugulare Tumor/metabolism , Glomus Jugulare Tumor/pathology , Glomus Tympanicum Tumor/metabolism , Glomus Tympanicum Tumor/pathology , Humans , Immunohistochemistry , Magnetic Resonance Imaging , Male , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/pathology , Nerve Degeneration , Paraganglioma/metabolism , Paraganglioma/pathology , Young AdultABSTRACT
After dedicated CT and MRI, Ga-DOTATATE PET/CT was performed in a patient with a temporal bone mass with primary diagnostic considerations of an endolymphatic sac tumor versus a glomus jugulotympanicum paraganglioma. The Ga-DOTATATE PET showed mild radiotracer uptake in the mass (SUVmax, 10.9). After surgical resection, pathology revealed an endolymphatic sac tumor. Immunohistochemical staining demonstrated somatostatin receptor type 2A expression in the vasculature of the mass, but not in the tumor cells.
Subject(s)
Ear Neoplasms/diagnostic imaging , Ear Neoplasms/pathology , Endolymphatic Sac/diagnostic imaging , Endolymphatic Sac/pathology , Organometallic Compounds/metabolism , Positron Emission Tomography Computed Tomography , Adult , Aged , Diagnosis, Differential , Ear Neoplasms/metabolism , Endolymphatic Sac/metabolism , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Paraganglioma/diagnosis , Receptors, Somatostatin/metabolismABSTRACT
PURPOSE: Synchrotron microbeam radiation therapy (MRT) is a method that spatially distributes the x-ray beam into several microbeams of very high dose (peak dose), regularly separated by low-dose intervals (valley dose). MRT selectively spares normal tissues, relative to conventional (uniform broad beam [BB]) radiation therapy. METHODS AND MATERIALS: To evaluate the effect of MRT on radioresistant melanoma, B16-F10 murine melanomas were implanted into mice ears. Tumors were either treated with MRT (407.6 Gy peak; 6.2 Gy valley dose) or uniform BB irradiation (6.2 Gy). RESULTS: MRT induced significantly longer tumor regrowth delay than did BB irradiation. A significant 24% reduction in blood vessel perfusion was observed 5 days after MRT, and the cell proliferation index was significantly lower in melanomas treated by MRT compared with BB. MRT provoked a greater induction of senescence in melanoma cells. Bio-Plex analyses revealed enhanced concentration of monocyte-attracting chemokines in the MRT group: MCP-1 at D5, MIP-1α, MIP-1ß, IL12p40, and RANTES at D9. This was associated with leukocytic infiltration at D9 after MRT, attributed mainly to CD8 T cells, natural killer cells, and macrophages. CONCLUSIONS: In light of its potential to disrupt blood vessels that promote infiltration of the tumor by immune cells and its induction of senescence, MRT could be a new therapeutic approach for radioresistant melanoma.
Subject(s)
Ear Neoplasms/radiotherapy , Melanoma, Experimental/radiotherapy , Radiation Tolerance , Synchrotrons , Animals , Cell Proliferation/radiation effects , Cellular Senescence , Ear Neoplasms/blood supply , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Female , Melanoma, Experimental/blood supply , Melanoma, Experimental/chemistry , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Monocyte Chemoattractant Proteins/metabolism , Staining and Labeling , Tumor Burden , Tumor Microenvironment , beta-GalactosidaseABSTRACT
Primary cutaneous acral CD8+ T-cell lymphoma (TCL) is a rare, distinct type of cutaneous TCL. Despite its worrisome histological appearance it has a benign clinical course. It is therefore important to recognize this as a distinct entity from other more aggressive CD8+ lymphomas, for which the management is very different.
Subject(s)
CD8-Positive T-Lymphocytes , Ear Neoplasms , Lymphoma, T-Cell, Cutaneous , Skin Neoplasms , Aged , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/pathology , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Humans , Lymphoma, T-Cell, Cutaneous/metabolism , Lymphoma, T-Cell, Cutaneous/pathology , Male , Skin Neoplasms/metabolism , Skin Neoplasms/pathologySubject(s)
CD8-Positive T-Lymphocytes , Ear Neoplasms , Ear, External , Lymphoma, T-Cell, Cutaneous , Neoplasm Recurrence, Local , Skin Neoplasms , Adult , Age Factors , Aged , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/pathology , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Ear, External/metabolism , Ear, External/pathology , Female , Humans , Lymphoma, T-Cell, Cutaneous/metabolism , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathologyABSTRACT
BACKGROUND/AIM: The rabbit auricular VX2 carcinoma is an established animal model for human head and neck squamous cell carcinoma (HNSCC). Previously, we observed that intraperitoneal oxidative (O3/O2) stress induced tumor remission. Our aim was to evaluate candidate genes associated with tumor regression. MATERIALS AND METHODS: For identification of tumor remission-related genes, microarray analysis was performed with subsequent validation by polymerase chain reaction (PCR), in situ hybridization, immunohistochemistry and western blot analysis. RESULTS: Microarray analysis indicated a prominent reduction of epidermal growth factor receptor (Egfr, Erbb1) expression levels in regressing tumors. Quantitative PCR confirmed a significant (p<0.005) down-regulation of Erbb1-3 mRNA in regressing VX2 tumors. Histological localization of Erbb1-3 mRNA transcript and protein indicated reduced Erbb gene expression occurring at the level of individual VX2 tumor cells rather than solely being an effect of tumor shrinkage. This study highlights changes in the Erbb gene signature of regressing VX2 carcinomas as a predictor for therapy response. The VX2 carcinoma animal model, therefore, appears suitable for the identification and evaluation of new diagnostic, prognostic and therapeutic biomarkers prior to their application in patients with HNSCC.
Subject(s)
Antineoplastic Agents/administration & dosage , Biomarkers, Tumor/genetics , Carcinoma, Squamous Cell/pathology , Ear Neoplasms/pathology , Gene Expression Profiling/methods , Animals , Antineoplastic Agents/pharmacology , Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Down-Regulation , Ear Neoplasms/drug therapy , Ear Neoplasms/genetics , Ear Neoplasms/metabolism , ErbB Receptors/genetics , ErbB Receptors/metabolism , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Injections, Intraperitoneal , Male , Neoplasm Transplantation , Oxygen/administration & dosage , Oxygen/pharmacology , Ozone/administration & dosage , Ozone/pharmacology , RabbitsSubject(s)
Ear Neoplasms/pathology , Meningeal Neoplasms/pathology , Meningioma/pathology , Skull Neoplasms/pathology , Temporal Bone/pathology , Biomarkers/metabolism , Ear , Ear Neoplasms/metabolism , Humans , Immunohistochemistry , Keratin-7/metabolism , Keratins/metabolism , Meningeal Neoplasms/metabolism , Meningioma/metabolism , Mucin-1/metabolism , Skull Neoplasms/metabolism , Tumor BurdenABSTRACT
Temporal bone squamous cell carcinoma (TBSCC) is an uncommon, aggressive malignancy with a poor prognosis in advanced cases. The dismal outcome is partially related to: the lack of reliable clinical or pathological prognostic factors and the largely unstandardized surgical and integrated treatments adopted. There is an undeniable need for novel diagnostic/therapeutic strategies to improve the prognosis. The purpose of this critical review was to explore the level of available knowledge concerning the molecular markers involved in the biology of TBSCC that have a prognostic potential. The Pub-Med and Scopus electronic databases were searched without publication date limits for studies investigating molecular markers in cohorts of patients with primary TBSCC. The search terms used were: "temporal bone cancer", "temporal bone carcinoma", "temporal bone malignancy", "ear cancer", "ear carcinoma", and "ear malignancy". We decided preliminarily not to consider series with less than five cases. Nine retrospective case series of TBSCC were found in which different analytical techniques had been used to study the role of several biomarkers (HPV, vimentin, transforming growth factor ß, CD105, RECK, matrix metalloproteinase-9, MASPIN, EBV, p16, TP53 mutation, pSTAT3, relaxin-2). CD105 expression (in tumor vessel endothelial cells) and MASPIN cytoplasmic expression (in carcinoma cells) were, respectively, found directly and inversely related with the neoplasm's recurrence rate. CD105 expression was also inversely related with disease-free survival in TBSCC. A future goal of such analyses should be to ascertain the radio- and chemo-sensitivity profiles of individual TBSCCs, enabling truly personalized therapies. A further, more ambitious goal will be to find targets for therapeutic agents that might prove crucial in improving the disease-specific survival for patients with advanced TBSCC.
Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/metabolism , Skull Neoplasms/metabolism , Temporal Bone , Adult , Aged , Carcinoma, Squamous Cell/pathology , Disease-Free Survival , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Female , Humans , Male , Middle Aged , Neoplasm Proteins/metabolism , Neoplasm Recurrence, Local , Prognosis , Retrospective Studies , Skull Neoplasms/pathology , Temporal Bone/surgeryABSTRACT
Adenomatous tumors in the middle ear and temporal bone are rare but highly morbid because they are difficult to detect prior to the development of audiovestibular dysfunction. Complete resection is often disfiguring and difficult because of location and the late stage at diagnosis, so identification of molecular targets and effective therapies is needed. Here, we describe a new mouse model of aggressive papillary ear tumor that was serendipitously discovered during the generation of a mouse model for mutant EGFR-driven lung cancer. Although these mice did not develop lung tumors, 43% developed head tilt and circling behavior. Magnetic resonance imaging (MRI) scans showed bilateral ear tumors located in the tympanic cavity. These tumors expressed mutant EGFR as well as active downstream targets such as Akt, mTOR and ERK1/2. EGFR-directed therapies were highly effective in eradicating the tumors and correcting the vestibular defects, suggesting these tumors are addicted to EGFR. EGFR activation was also observed in human ear neoplasms, which provides clinical relevance for this mouse model and rationale to test EGFR-targeted therapies in these rare neoplasms.
Subject(s)
Adenoma/metabolism , Ear Neoplasms/metabolism , Ear, Middle/metabolism , ErbB Receptors/metabolism , Neoplasms, Experimental/metabolism , Skull Neoplasms/metabolism , Temporal Bone/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adenoma/drug therapy , Adenoma/pathology , Animals , Antineoplastic Agents/pharmacology , Behavior, Animal , Drug Design , Ear Neoplasms/drug therapy , Ear Neoplasms/genetics , Ear Neoplasms/pathology , Ear, Middle/drug effects , Ear, Middle/pathology , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/genetics , Female , Genotype , Humans , Magnetic Resonance Imaging , Male , Mice, Transgenic , Molecular Targeted Therapy , Motor Activity , Mutation , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/genetics , Neoplasms, Experimental/pathology , Phenotype , Promoter Regions, Genetic , Pulmonary Surfactant-Associated Protein C/genetics , Signal Transduction/drug effects , Skull Neoplasms/drug therapy , Skull Neoplasms/pathology , Temporal Bone/drug effects , Temporal Bone/pathology , Uteroglobin/genetics , Uteroglobin/metabolism , X-Ray MicrotomographyABSTRACT
OBJECTIVES/HYPOTHESIS: The purpose of the present study is to explore, demonstrate, and describe the expression of genes related to the innate immune system in the human endolymphatic sac. It is hypothesized that the endolymphatic sac has a significant immunological function in the human inner ear. STUDY DESIGN: DNA microarrays and immunohistochemistry were used for analyses of fresh human endolymphatic-sac tissue samples. METHODS: Twelve tissue samples from the human endolymphatic sac were obtained during translabyrinthine surgery for vestibular schwannoma. Microarray technology was used to investigate tissue sample gene expression using adjacent dura mater as control. The expression of genes specific for the innate immune system was determined and results for selected key molecules verified by immunohistochemistry. RESULTS: A comprehensive overview of expressed genes of the innate immune system was obtained. Multiple key elements of both the cellular and humoral innate immune system were expressed, including Toll-like receptors 4 and 7, as well as beta-defensin and lactoferrin. CONCLUSIONS: The present data provides the first direct evidence of an immunological capacity of the human endolymphatic sac. At the molecular level, the endolymphatic sac is capable of antigen recognition and processing for initiation of an immune response. In addition, potent molecules directly toxic to invading pathogens are expressed by the sac epithelium. This evidence strongly supports the endolymphatic sac as a significant immunological entity of the inner ear. LEVEL OF EVIDENCE: N/A.
Subject(s)
Biomarkers, Tumor/genetics , DNA, Neoplasm/genetics , Endolymphatic Sac/immunology , Gene Expression Regulation, Neoplastic , Immunity, Innate/genetics , Adult , Aged , Biomarkers, Tumor/biosynthesis , Ear Neoplasms/genetics , Ear Neoplasms/metabolism , Ear Neoplasms/pathology , Endolymphatic Sac/metabolism , Endolymphatic Sac/pathology , Humans , Immunohistochemistry , Middle Aged , Neurilemmoma/genetics , Neurilemmoma/metabolism , Neurilemmoma/pathology , Oligonucleotide Array Sequence Analysis/methodsABSTRACT
OBJECTIVE: There is ongoing debate on the pathogenic mechanisms of cholesterol granuloma formation in the temporal bone. The purpose of this report is to provide evidence in support of the exposed marrow hypothesis in explaining the pathogenesis of petrous apex cholesterol granuloma. STUDY DESIGN: Retrospective single case study. MAIN OUTCOME MEASUREMENT: The primary outcome evaluated was the diagnosis of a new cholesterol granuloma in a petrous apex that previously demonstrated radiologic evidence of bone marrow exposed to petrous apex air cells. RESULTS: A patient with a unilateral petrous apex cholesterol granuloma develops a new, contralateral cholesterol granuloma in a hyperpneumatized temporal bone petrous apex shown previously to have medullary bone exposed to air cells. CONCLUSION: This report implicates the medullary-air cell interface in a hyperaerated temporal bone petrous apex in the development and growth of a petrous apex cholesterol granuloma.
Subject(s)
Cholesterol/metabolism , Ear Neoplasms/pathology , Granuloma/pathology , Petrous Bone/pathology , Temporal Bone/pathology , Bone Marrow/pathology , Ear Neoplasms/diagnosis , Ear Neoplasms/metabolism , Female , Granuloma/diagnosis , Granuloma/metabolism , Humans , Middle Aged , Petrous Bone/metabolism , Temporal Bone/metabolism , Tomography, X-Ray ComputedSubject(s)
Ear Canal , Ear Neoplasms/pathology , Seminoma/pathology , Adenoma/metabolism , Adenoma/pathology , Adult , Alkaline Phosphatase/metabolism , Antibodies, Monoclonal, Murine-Derived/metabolism , Diagnosis, Differential , Ear Neoplasms/metabolism , Ear Neoplasms/radiotherapy , Ear Neoplasms/surgery , GPI-Linked Proteins/metabolism , Humans , Isoenzymes/metabolism , Lymphoma, Large-Cell, Anaplastic/metabolism , Lymphoma, Large-Cell, Anaplastic/pathology , Male , Mast-Cell Sarcoma/metabolism , Mast-Cell Sarcoma/pathology , Proto-Oncogene Proteins c-kit/metabolism , Seminoma/metabolism , Seminoma/radiotherapy , Seminoma/surgery , Vimentin/metabolism , Young AdultABSTRACT
We present a case of a papillary tumour at the cerebellopontine angle in a 41-year-old man. He presented with left-sided facial and ear pain associated with dizziness, nystagmus and hearing loss. CT scan of the temporal bone showed a destructive tumour at the left cerebellopontine angle. Surgical excision was performed and the diagnosis of the endolymphatic sac tumour was made. Endolymphatic tumour is a low grade adenocarcinoma that originates from the endolymphatic sac. The definitive diagnosis requires a combination of clinical features, radiological finding and pathological correlation.
Subject(s)
Adenocarcinoma, Papillary/pathology , Ear Neoplasms/pathology , Endolymphatic Sac/pathology , Adenocarcinoma, Papillary/metabolism , Adenocarcinoma, Papillary/therapy , Adult , Biomarkers, Tumor/metabolism , Combined Modality Therapy , Ear Neoplasms/metabolism , Ear Neoplasms/therapy , Endolymphatic Sac/metabolism , Endolymphatic Sac/surgery , Glial Fibrillary Acidic Protein/metabolism , Humans , Male , Mucin-1/metabolism , Neoplasm Invasiveness , Neoplasm, Residual/diagnosis , Neoplasm, Residual/radiotherapy , Temporal Bone/pathology , Treatment OutcomeABSTRACT
The endolymphatic sac tumor (ELST) is a low-grade carcinoma originating in the ear. These extremely rare tumors are capable of invading the cerebellopontine angle and might be mistaken for choroid plexus tumors (CPTs) in this region. Currently, these tumors are distinguished by conventional morphologic and immunohistochemical studies for S-100, cytokeratin, and GFAP expression, but all markers are variably expressed by both tumors. Therefore, we examined new promising markers such as EAAT-1 and Kir7.1 in 4 ELSTs and 35 CPTs located in the fourth ventricle or at the cerebellopontine angle in adults. Immunohistochemical expression of Kir7.1 was found in 30 (100%) of 30 and EAAT-1 in 32 (91%) of 35 CPTs tested and was absent in all ELSTs. Expression of GFAP was found in 16 (55%) and S-100 in 29 (100%) of 29 CPTs tested, but both markers were also expressed in 2 of 4 ELSTs examined. Specificity and sensitivity of Kir7.1 (both 100%) and EAAT-1 (100% and 91%, respectively) were superior to the values for S-100 (50% and 100%, respectively) and GFAP (50% and 55%, respectively) for distinguishing CPT from ELST.
Subject(s)
Carcinoma/diagnosis , Choroid Plexus Neoplasms/diagnosis , Ear Neoplasms/diagnosis , Endolymphatic Sac/metabolism , Excitatory Amino Acid Transporter 1/metabolism , Potassium Channels, Inwardly Rectifying/metabolism , Adult , Biomarkers, Tumor/metabolism , Carcinoma/metabolism , Carcinoma/pathology , Cerebellopontine Angle/metabolism , Cerebellopontine Angle/pathology , Choroid Plexus Neoplasms/metabolism , Choroid Plexus Neoplasms/pathology , Diagnosis, Differential , Ear Neoplasms/metabolism , Endolymphatic Sac/pathology , Female , Humans , Male , Middle Aged , Sensitivity and SpecificityABSTRACT
Middle ear adenomas (MEAs) are benign neoplasms along a spectrum with neuroendocrine neoplasms (carcinoid tumors). Immunohistochemical (IHC) staining for myoepithelial markers has not been reported in these tumors. The archives of the Cleveland Clinic, University of Virginia and Armed Forces Institute of Pathology were retrospectively searched for tumors arising within the middle ear with material available for IHC staining. Twelve cases of MEAs, four cases of jugulotympanic paragangliomas (JPGs), 10 cases of ceruminous adenomas (CAs) and four cases of ceruminous adenocarcinomas (CACs) were obtained. IHC staining was performed for smooth muscle actin (SMA), p63, S-100 protein, cytokeratin 5/6 (CK5/6), and cytokeratin 7 (CK7). The MEAs were positive for: CK7 (92 %, luminal), CK5/6 (92 %, abluminal), p63 (83 %, abluminal), and negative for SMA and S-100 protein. The JPGs were negative for CK7, CK5/6, p63 and SMA; S-100 protein highlighted sustentacular cells. The CAs were positive for: CK7 (100 %, luminal), CK5/6 (100 %, abluminal), S-100 protein (80 %, abluminal), p63 (100 %, abluminal), and SMA (90 %, abluminal). CACs demonstrated two patterns, (1) adenoid cystic carcinoma-type: positive for CK7 (100 %, luminal), CK5/6, S-100 protein, p63, and SMA (all 100 %, abluminal); and (2) conventional-type: CK7 (50 % luminal), and no CK5/6, SMA, S-100 protein, or p63 expression. The IHC profile of MEAs suggests that these tumors harbor at least two cell populations, including luminal and basal cells. However, unlike ceruminous adenomas, MEAs lack true myoepithelial differentiation given the absence of S-100 protein and SMA staining in all cases.
Subject(s)
Adenoma/pathology , Cell Differentiation , Ear Neoplasms/pathology , Ear, Middle/pathology , Epithelial Cells/pathology , Muscle, Smooth/pathology , Adenocarcinoma/pathology , Adenoma/metabolism , Adolescent , Adult , Aged , Diagnosis, Differential , Ear Neoplasms/metabolism , Epithelial Cells/metabolism , Female , Humans , Immunohistochemistry , Male , Middle Aged , Muscle, Smooth/metabolism , Paraganglioma/pathology , Retrospective Studies , Young AdultABSTRACT
OBJECTIVES: Ceruminous adenoma of the external auditory canal (EAC) is a rare type of tumour that is diagnosed histologically. However, the clinical behaviour of these tumours remains controversial. Here, we report a case of ceruminous adenoma of the EAC and expression of a hypoxia marker. CASE REPORT: A 78-year-old man presented with a 6-month history of recurrent otorrhoea in the right ear. Surgery was performed by the transmeatal approach with total removal of the mass. Histopathology revealed a ceruminous adenoma. Tumour cells were positive for CK, S-100 protein, Glut-1, HIF-1α, PI3K and p-Akt. There was no evidence of recurrence at last follow-up 27 months after the operation. CONCLUSIONS: Ceruminous adenoma of the EAC is a rare tumour. The treatment of choice is wide local excision with clear margins. To our knowledge, this is the first report of Glut-1 expression and the PI3K/Akt pathway in ceruminous adenoma of the EAC.
Subject(s)
Adenoma/metabolism , Ear Neoplasms/metabolism , Glucose Transporter Type 1/biosynthesis , Hypoxia-Inducible Factor 1, alpha Subunit/biosynthesis , Oncogene Protein v-akt/biosynthesis , Phosphatidylinositol 3-Kinases/biosynthesis , Adenoma/diagnosis , Adenoma/genetics , Adenoma/pathology , Aged , Cerumen/metabolism , Ear Canal/metabolism , Ear Canal/pathology , Ear Neoplasms/diagnosis , Ear Neoplasms/genetics , Ear Neoplasms/pathology , Glucose Transporter Type 1/genetics , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Male , Oncogene Protein v-akt/genetics , Phosphatidylinositol 3-Kinases/geneticsABSTRACT
Endolymphatic sac tumor (ELST) is a rare neoplasm which can be encountered sporadically or in Von Hippel-Lindau (VHL) disease. Here we report a sporadic case of ELST in 31-year-old man. Neither the symptoms nor a family history of VHL disease were found in the patient. CT imaging demonstrated an expansile lytic lesion of the mastoid process of the left petrous bone. MR scanning revealed a 5.2 cm × 4.7 cm × 4.2 cm mass which showed hyperintensity on T1- and T2-weighted images. Histologic sections showed a papillary, cystic or glandular architecture. The papillary and glandular structures were lined by a single layer of flattened cuboidal-to-columnar cells. The stroma of the papillary fronds was richly vascularized and chronically inflamed. The tumor showed diffusely positive reactivity with cytokeratin (Pan), cytokeratin 19, cytokeratin 5/6, cytokeratin 7, EMA, vimentin, CD56, and NSE and also showed variable reactivity with glial fibrillary acidic protein (GFAP) and VEGF. The Ki-67 immunostain showed a proliferation index of < 1%. Because the mass was large, it was difficult to extirpate surgically. After surgery, the patient underwent gamma-knife radiosurgery for residual tumor. The findings indicate that ELST is a rare neoplasm with benign histopathological appearance and clinically destructive behavior. Because of the rarity of this tumor, it can easily be confused with other tumors such as paraganglioma, middle ear adenoma, adenocarcinoma, papillary carcinoma of thyroid or choroid plexus papilloma. Owing to its locally aggressive nature, it is difficult to extirpate surgically when it is large. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7973320646763012.
Subject(s)
Adenocarcinoma/diagnosis , Ear Neoplasms/diagnosis , Endolymphatic Sac , Adenocarcinoma/metabolism , Adenocarcinoma/surgery , Adult , Ear Neoplasms/metabolism , Ear Neoplasms/surgery , Humans , Keratin-19/metabolism , Keratin-7/metabolism , Male , Radiosurgery , Treatment OutcomeABSTRACT
The negative feedback regulation of epidermal growth factor receptor (EGFR) and other tyrosine kinase receptors, including receptor dephosphorylation and endocytosis followed by degradation, is becoming recognized as a major determinant of receptor function. To evaluate the significance of the negative regulation of EGFR during carcinogenesis in vivo, we subjected the mutant mouse line Dsk5, in which the intrinsic activation of the receptor due to a point mutation is normally counterbalanced by increased posttranslational receptor down-regulation, to skin chemical carcinogenesis. Dsk5 mice showed reduced tumor numbers and tumor burden compared with control littermates, and Dsk5-derived tumors showed a reduction in the activation and total levels of EGFR. Furthermore, the transcript levels of several molecules known to act as negative regulators of EGFR were significantly increased in Dsk5-derived tumors. Another intriguing observation was the appearance of tumors with sebaceous differentiation in the ears of Dsk5 mice after chemical carcinogenesis. Further studies are necessary to reveal whether these tumors represent a cell type-specific evasion from EGFR negative feedback machinery. In conclusion, this study reveals that several negative feedback regulators contribute to suppression of the intrinsic activation of mutant EGFR during skin carcinogenesis, stressing the potential exploitation of negative regulators as either therapeutic targets or diagnostic tools in cancer and other diseases.